MCP-1 levels are increased in CSF of patients with Alzheimer's disease (AD) compared with controls, suggesting a role in the development of dementia. Recently, a biallelic A/G polymorphism in the MCP-1 promoter at position -2518 has been found, influencing the level of MCP-1 expression in response to an inflammatory stimulus. The distribution of the A-2518G SNP was determined in 269 AD patients and in 203 healthy age matched controls, showing no differences between the two groups. On the contrary, a significant increase of MCP-1 serum levels in AD patients carrying at least one G mutated allele was observed. Moreover, the highest peaks of MCP-1 serum levels were present in patients carrying two G alleles. Stratifying by ApoE genotype, gender or age at onset, no differences in both allele frequency and MCP-1 serum concentration were observed. The A-2518G polymorphism in MCP-1 gene does not seem to be a risk factor for the development of AD, but its presence correlates with higher levels of serum MCP-1, which can contribute to increase the inflammatory process occurring in AD.

MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels / C. Fenoglio, D. Galimberti, C. Lovati, I. Guidi, A. Gatti, S. Fogliarino, M. Tiriticco, C. Mariani, G. Forloni, C. Pettenati, P. Baron, G. Conti, N. Bresolin, E. Scarpini. - In: NEUROBIOLOGY OF AGING. - ISSN 0197-4580. - 25:9(2004), pp. 1169-1173.

MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels

C. Fenoglio
Primo
;
D. Galimberti
Secondo
;
C. Lovati;I. Guidi;C. Mariani;N. Bresolin
Penultimo
;
E. Scarpini
Ultimo
2004

Abstract

MCP-1 levels are increased in CSF of patients with Alzheimer's disease (AD) compared with controls, suggesting a role in the development of dementia. Recently, a biallelic A/G polymorphism in the MCP-1 promoter at position -2518 has been found, influencing the level of MCP-1 expression in response to an inflammatory stimulus. The distribution of the A-2518G SNP was determined in 269 AD patients and in 203 healthy age matched controls, showing no differences between the two groups. On the contrary, a significant increase of MCP-1 serum levels in AD patients carrying at least one G mutated allele was observed. Moreover, the highest peaks of MCP-1 serum levels were present in patients carrying two G alleles. Stratifying by ApoE genotype, gender or age at onset, no differences in both allele frequency and MCP-1 serum concentration were observed. The A-2518G polymorphism in MCP-1 gene does not seem to be a risk factor for the development of AD, but its presence correlates with higher levels of serum MCP-1, which can contribute to increase the inflammatory process occurring in AD.
Settore MED/26 - Neurologia
2004
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/26051
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 74
  • ???jsp.display-item.citation.isi??? 67
social impact